KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash from Financing Activities (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Cash from Financing Activities data on record, last reported at $1.5 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 80.91% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $3.4 million, up 107.97%, while the annual FY2025 figure was $3.4 million, 107.97% up from the prior year.
  • Cash from Financing Activities reached $1.5 million in Q3 2025 per PACB's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $865.7 million in Q1 2021 and bottomed at -$81.6 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $69.4 million, with a median of $1.4 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 4656.97% in 2021, then tumbled 10063.61% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.3 million in 2021, then tumbled by 38.14% to $819000.0 in 2022, then crashed by 10063.61% to -$81.6 million in 2023, then surged by 38.48% to -$50.2 million in 2024, then surged by 102.93% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $1.5 million in Q3 2025, $2.0 million in Q1 2025, and -$50.2 million in Q4 2024.